Bui Lecture.pdf

More documents

Recommendations

Info

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, M.D., Steven J. O’Day, M.D., David F. McDermott, M.D., Robert W. Weber, M.D., Jeffrey A. Sosman, M.D., John B. Haanen, M.D., Rene Gonzalez, M.D., Caroline Robert, M.D., Ph.D., Dirk Schadendorf, M.D., Jessica C. Hassel, M.D., Wallace Akerley, M.D., Alfons J.M. van den Eertwegh, M.D., Ph.D., Jose Lutzky, M.D., Paul Lorigan, M.D., Julia M. Vaubel, M.D., Gerald P. Linette, M.D., Ph.D., David Hogg, M.D., Christian H. Ottensmeier, M.D., Ph.D., Celeste Lebbe, M.D., Christian Peschel, M.D., Ian Quirt, M.D., Joseph I. Clark, M.D., Jedd D. Wolchok, M.D., Ph.D., Jeffrey S. Weber, M.D., Ph.D., Jason Tian, Ph.D., Michael J. Yellin, M.D., Geoffrey M. Nichol, M.B., Ch.B., Axel Hoos, M.D., Ph.D., and Walter J. Urba, M.D., Ph.D. NEJM, August 19 2010
Cancer immunoediting describes the process by which tumor cells, in order to escape immune responses, develop immune evasive measures. A prediction from this model is that tumors that develop in immune competent people are already immune evasive.
Page 1 and 2:
Tumor Immunology Jack Bui, MD, PhD
Page 4 and 5:
Tumor immunology = the study of wha
Page 6 and 7:
Immune cells function to eliminate
Page 8 and 9:
Figure 15.12d The Biology of Cancer
Page 10 and 11:
The birth of tumor immunosurveillan
Page 12:
Paradigm shift : Cancers are opport
Page 15:
Shankaran et al., Nature 2001 Mice
Page 18 and 19:
The presence of tumor specific T ce
Page 20 and 21:
Evidence for tumor immunosurveillan
Page 22 and 23:
Shown is survival in ovarian cancer
Page 24:
Endogenous T Cell Responses to Anti
Page 28 and 29: Goals 1. Present evidence that the
Page 30 and 31: Shankaran et al., Nature 2001 WT tu
Page 32 and 33: Cancer immunoediting: regressor tum
Page 35 and 36: Evidence for equilibrium • Human
Page 37 and 38: Melanoma complicating treatment wit
Page 39 and 40: Implications of equilibrium state
Page 41 and 42: Inflammation and Cancer: “Cancers
Page 43 and 44: Evidence for inflammation induced c
Page 45 and 46: Deletion of the NF-kB activator IKK
Page 47 and 48: Goals 1. Present evidence that the
Page 49 and 50: Evidence for Cancer Immunoediting:
Page 51 and 52: Normal cell Not recognized Induced-
Page 53 and 54: Gasser et al., DNA damage induces N
Page 55 and 56: Evidence for p53’s role in activa
Page 57 and 58: Corollary to Cancer Immunoediting:
Page 59 and 60: Passenger mutations leading to neo-
Page 61 and 62: Oncogene-driven models of cancer ca
Page 63 and 64: Goals for this hour 1. Present evid
Page 65 and 66: What cells/molecules promote vs inh
Page 67 and 68: Immune therapy of melanoma • IL-2
Page 69: Peripheral blood mononuclear cells
Page 74 and 75: An example of immunotherapy
Page 76 and 77: The presence of tumor specific T ce
Page 78: Can we remove immune suppression?
Page 83: Some major unanswered questions •
show all

Bui Lecture.pdf

Create successful ePaper yourself

Delete template?

Save as template?